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Abstract
Background: There is a high prevalence of  gastro-duodenal disease in sub-Saharan Africa. Peptic ulcer disease in dyspeptic 
patients, 24.5%, was comparable to prevalence of  gastro-duodenal disease among symptomatic individuals in developed coun-
tries (12 – 25%). Limited data exists regarding its associated risk factors despite accumulating evidence indicating that gastro-
duodenal disease is common in Ghana.
Objectives: This study investigates risk factors associated with gastro-duodenal disease at the Korle-Bu Teaching Hospital, Ac-
cra, Ghana.
Methods: This study utilized a cross-sectional design to consecutively recruit patients referred with upper gastro-intestinal 
symptoms for endoscopy. The study questionnaire was administered to study participants. Helicobacter pylori infection was con-
firmed by rapid-urease examination at endoscopy.
Results:  Of  242 patients sampled; 64 had duodenal ulcer, 66 gastric ulcer, 27gastric cancer and 64 non-ulcer dyspepsia. Nine-
teen (19) had duodenal and gastric ulcer while 2 had gastric ulcer and cancer. A third (32.6%) of  patients had history of  NSAID-
use. H. pyloriwas associated with gastric ulcer (p=0.033) and duodenal ulcer (p=0.001). There was an increased prevalence of  
duodenal ulcer in H. pylori-infected patients taking NSAIDs, P=0.003. 
Conclusion: H. pylori was a major risk factor for peptic ulcer disease. However, NSAID-related gastro-duodenal injury has been 
shown to be common in H. pylori infected patients. It highlights the need for awareness of  the adverse gastro-intestinal effects 
in a H. pylori endemic area.
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Gastro-duodenal disease is common in Africa1. Compar-
ative studies showed considerable variation in the prevale
nce of  duodenal ulceration in different parts of  Africa: 
the coastal region of  West Africa and Congo were high 
prevalence areas while the Northern savannah of  Afri-
ca was a low prevalence region2. The advent of  flexible 
endoscopy in its evaluation increased the sensitivity and 
specificity of  gastro-duodenal disease diagnosis. It has 
now become apparent that clearly there is a high preva-
lence of  gastro-duodenal disease existing throughout Af-
rica including historically lower prevalence areas2. In fact 
the overall prevalence of  peptic ulcer in dyspeptic patients 
was 24.5% which is represented in the upper range of  
12 – 25% of  the prevalence of  gastro-duodenal disease 
among symptomatic individuals in developed countries1.
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A study at the Korle-Bu Teaching Hospital (KBTH) 
Endoscopy Unit, the major tertiary centre in Ghana, re-
viewed 6977 upper gastro-intestinal (GI) endoscopies 
between January 1995 and December 20023. Chronic 
duodenal ulcer (DU) 19.6%, gastritis 12.7%, duodenitis 
10.2% and oesophagitis 7.5% were the most frequent di-
agnoses3. Normal endoscopic findings were more com-
mon in young patients and represented 41.1% of  cases3. 
Another study at the KBTH looked at the incidence of  
Helicobacter pylori (H. pylori) infection by rapid-urease-
testing in 130 Ghanaian patients referred for upper-GI 
endoscopy4. Three-quarters tested positive for H. pylori4. 
While 23.5% of  H. pylori-positive patients had active pep-
tic ulcers, 18.8% of  H. pylori-negative patients also had ul-
cer4. Out of  43 patients with normal upper-GI endoscopy, 
74.4% were H. pylori-positive4. This emphasizes a com-
plex inter-play of  a number of  factors (environmental, 
host, microbial) in the pathogenesis of  gastro-duodenal 
disease in Ghana. Non-steroidal anti-inflammatory drug 
(NSAID)-use is another of  such risk factors for peptic 
ulcer formation through several mechanisms including 
suppression of  gastric prostaglandin synthesis and inter-
ference with the repair of  superficial injury5. Limited data 
exists regarding its use and inter-relationship with other 
important factors such as H. pylori in addition to smok-
ing and alcohol consumption, despite accumulating evi-
dence indicating that gastro-duodenal disease is common 
in Ghana. The objective of  this hospital-based study was 
to investigate the relationship between these risk factors 




This study used a cross-sectional design to consecutively 
recruit medical in-patients and clinic out-patients referred 
to the Endoscopy Unit of  the KBTH with upper gastro-
intestinal symptoms for endoscopy.
Study setting
Korle-Bu Teaching Hospital has 2,500 beds and is the 
main tertiary referral centre in Accra serving the major-
ity of  the Southern half  of  Ghana. It offers a breadth 
of  medical and surgical sub-specialty services includ-
ing gastroenterology and endoscopy. Study participant 
recruitment and data collection was performed at the 
Endoscopy Unit, KBTH, between 2010 and 2012. The 
Endoscopy Unit is staffed by medical and surgical gas-
troenterologists with the support of  trained nurses and 
auxiliary staff. It uses both Olympus and Storz video-
endoscopy equipment for endoscopic procedures. It runs 
eight (three hour) endoscopy sessions per week and of-
fers both upper and lower GI endoscopy services. Each 
session performs approximately 10 upper endoscopies 
and 3 lower endoscopies. Procedures performed are both 
diagnostic and interventional. The latter include injection 
sclerotherapy, variceal banding, polypectomy,stent inser-
tion and endotherapy for bleeding ulcers.
Study participants
Medical inpatients and clinic out-patients with gastro-
intestinal symptoms referred to the Endoscopy Unit, 
KBTH were enrolled into the study. Study participants 
were consecutively recruited at two scheduled endoscopy 
sessions each week by convenience sampling. All patients 
were taken explanatory statements of  the project and 
consented prior to endoscopy. Patients with previous H. 
pylori eradication treatment or proton-pump inhibitor-use 
two weeks preceding endoscopic analysis and patients 
with oesophageal disease were excluded from further 
study. Korle-Bu receives out-patient referrals from sever-
al primary and specialist centres across Southern Ghana. 
One hundred and seven (44.2%) were clinic out-patients 
while 135 (55.8%) were in-patients.
Study variables, data sources and measurement
Gastro-intestinal  symptoms, medications such as NSAID 
use, alcohol intake and smoking history was taken. Re-
ported gastrointestinal symptoms included dyspepsia as 
well as vomiting, anorexia, upper GI bleeding, weight loss 
and dysphagia. Dyspepsia was defined as one or more of  
the following symptoms: post-prandial fullness, early sa-
tiation (inability to eat a normal sized meal) and epigastric 
pain/burning according to the Rome III criteria6.
Upper gastro-intestinal endoscopy was performed us-
ing the Olympus CV-160 videoscope. Study participants 
were given the option of  sedation with (intravenous mid-
azolam 2mg) or lignocaine throat spray. H. pylori infec-
tion was determined by the rapid-urease-campylobacter-
like-organism (CLO) test on antral biopsies at upper-GI 
endoscopy (specificity 98%, sensitivity >93%; Cambridge 
Life Sciences Ltd, Cambridge, UK). Diagnoses captured 
with the study questionnaire included duodenal ulcer/
erosion (DU), gastric ulcer/erosion (GU), gastric carci-
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noma (GCA) and non-ulcer dyspepsia. The latter includ-
ed patients with either endoscopic gastritis only (n=36) 
or normal endoscopy (n=28). The location and number 
of  lesions were recorded. The diameter of  ulcers was 




Data was first entered into Excel spread-sheet and fur-
ther analysed by SPSS 16 Program. Chi-square was used 
to demonstrate differences between observed variables 
with a p value of  <0.05 used to indicate statistical sig-
nificance. Categorical data was expressed as proportions 
and presented in tables and bar charts. Ethical approval 
was granted by the Protocol Review Committee of  the 
University of  Ghana Medical School, College of  Health 
Sciences, University of  Ghana.
 
Results
Baseline characteristics of  study participants
Approximately eighty patients attended the Endoscopy 
Unit, KBTH for upper GI endoscopy each week. Twenty 
patients were examined each week for eligibility of  whom 
242 patients were sampled during the study period. Main 
reasons for non-participation in the study included recent 
antibiotic or proton-pump inhibitor use. One hundred 
and fifteen (47.5%) were females and 127 (52.5%) males. 
The mean age of  patients was 51.4 years, SD 18.6, (me-
dian 52 yrs; range 15-95 yrs).Sixty-eight-percent (68%) of  
patients had dyspepsia, the commonest clinical presen-
tation encountered, table 1. Other symptoms included 
vomiting (6%), haematemesis and/or melaena (14%), an-
orexia (3%), weight loss (1%). The commonest physical 
sign was pallor, (25%) n = 61, followed by abdominal 
tenderness, (14%) n = 34. Twenty-six-percent, (n = 63) 
did not have any abnormal physical signs, table 1.  In this 
study, presenting clinical features (symptoms, physical 
signs) were not associated with the endoscopic diagnoses 
and no combination of  symptoms or signs reliably pre-
dicted diagnosis.
Table 1: Symptoms and physical signs elicited in patients enrolled at the  
Endoscopy Unit, KBTH 
 
Symptom N % 
Dyspepsia 165 68.0 
Vomiting 6 6.0 
Haematemesis and/or melaena 34 14.0 
Anorexia 7 3.0 
Weight loss 2 1.0 
Dysphagia 1 1.0 
Other 17 7.0 
Total 242 100.0 
Physical signs     
Abdominal mass 15 6.2 
Abdominal tenderness 34 14.0 
Jaundice 5 2.0 
Pallor 61 25.2 
Obesity 21 8.7 
Cachexia 35 14.5 
Clubbing 4 1.7 
Ascites, hepatomegaly 2 0.8 
hepatomegaly 2 0.8 
No signs 63 26.0 
Total 242 100.0 
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Endoscopy and histopathology findings
Following endoscopy, 64 had DU, 66 GU, 27 GCA and 
64 non-ulcer dyspepsia (NUD). Additionally, nineteen 
(19) had both DU and GU while 2 had GU and GCA. 
Majority (90.8%) of  GUs were distal with pre-pyloric ul-
cers accounting for 55.2% of  all GUs (Table 2). A third 
(34.5%) of  patients with GU had multiple (2 or more) 
lesions. Most duodenal ulcers were solitary (78.3%), how-
ever 19.3% were large (>2cm) and 1 in 5 patients (21.7%) 
had two or more ulcers. Most cancers were large, involv-
ing the gastric antrum and/or body, with 17.2% showing 
evidence of  gastric outlet obstruction (Table 2). Histol-
ogy on nineteen (19) of  the 29 GCA patients confirmed 
adenocarcinoma in all cases (100%). Fifteen were intesti-
nal while 4 had diffuse-adenocarcinoma.
Factors associated with gastro-duodenal disease
There was a strong association between GU prevalence 
and age with 63.1% over 50 years (p = 0.0001); GUs 
were also more common in males (60.9% vs. 39.1 %; p = 
0.049). Conversely, DUs did not demonstrate a significant 
relationship with either age or gender. Eighty-percent 
(80%) of  patients with GCA were over 50 years.  
Table 3 illustrates the prevalence of  H. pylori in patients 
with non-ulcer dyspepsia, gastric ulcer, duodenal ulcer 
and gastric cancer. Gastric and duodenal ulceration had 
strong statistically significant associations with H. pylori, 
however gastric cancer did not achieve the requisite sig-
nificance level (p = 0.220). There was a lower prevalence 
of  H. pylori infection and NSAID-use among patients 
with non-ulcer dyspepsia in comparison with patients 
with gastric ulcer, duodenal ulcer and gastric cancer, table 
3 and 4. 
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Table 3: the prevalence of H. pylori infection in non-ulcer dyspepsia, 






















34 (53.1%) 30 (46.9%) 64 0.0001 21.67 
  
0.0001 
Gastric ulcer 72 (82.8%) 15 (17.2%) 87 0.033 4.571 0.044 
Duodenal ulcer 73 (88.0%) 10 (12.0%) 83 0.001 11.602 0.001 
Gastric cancer 19 (65.5%) 10 (34.5%) 29 0.220 1.504 0.255 
  
  
Table 4: the prevalence of NSAID-use in non-ulcer dyspepsia, peptic  








Total P-value Chi 
square 
(df = 1) 
Fisher 
exact test 
Non-ulcer dyspepsia 12 
(18.8%) 
52 (81.2%) 64 0.006 7.640 0.005 
Gastric ulcer 34 
(39.1%) 
53(60.9%) 87 0.110 2.559 0.194 
Duodenal ulcer 32 
(38.6%) 
51(61.4%) 83 0.157 2.006 0.118 







Non-steroidal anti-inflammatory drugs (NSAIDs) were 
used in 32.6% (n = 79) of  patients sampled. These in-
cluded local/over-the-counter preparations of  diclofenac 
(75-100mg), ibuprofen (200-400mg) and aspirin (75mg) 
therapy. Non-steroidal anti-inflammatory drug-use was 
associated with an increased prevalence of  DU in H. py-
lori-infected patients (Table 5).  
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Table 5: H. pylori infection, NSAID-use and gastro-duodenal disease 
 
H. pylori and NSAID-use 
  
  
Chi square (df= 4) 
DU 
(n/%) 








p = 0.141 
5.468 
CLO (+) and NSAID (+): (n=58) 28 (48.3) 28 (48.3) 3 (5.2) 
CLO (+) and NSAID (-): (n=123) 45 (36.6) 44 (35.8) 16 (13.0) 
CLO (-) and NSAID (+): (n=21) 4 (19.0) 6 (28.6) 5 (23.8) 
CLO (-) and NSAID (-): (n=40) 6 (15.0) 9 (22.5) 5 (12.5) 
 
          CLO (+):  H. pylori-positive infection 
          CLO (-):   H. pylori-negative infection 
          NSAID (+):  NSAID-use 
          NSAID (-):  No NSAID-use 
Following multi-variate analysis of  all patients, H. pylori-
infected patients were more likely than other patients to 
have peptic ulcer disease, table 5 (GU OR 2.4 CI 1.2-
4.8; DU OR 3.5 1.6-7.5). Three (1.2%) study participants 
were current smokers while 25 (10.3%) had a past history 
of  smoking. Sixty-two (25.6%) study participants indi-
cated regular alcohol intake in relation to 37 (15.3%) who 
had a past history of  alcohol consumption. There was no 
demonstrable statistical significant association between 
smoking, alcohol consumption, herbal medication-use 
and gastro-duodenal disease.
Table 6: Relationship between predictor variables and gastro-duodenal  






OR       (CI) 
DU 
n=83 
OR       (CI) 
GCA 
n=29 
(OR)       (CI) 
NUD 
n=64 
(OR)    (CI) 
Age 0.7 0.6- 0.9 1.1 0.9-1.3 0.7 0.5-0.9 1.5 1.2-1.8 
Herbal use (50) 0.7 0.4-1.3 0.7 0.4-1.2 2.3 0.9-5.4 0.9 0.5-1.7 
Smoking (1.2) 0.9 0.4-2.4 1.2 0.5-3.0 1.1 0.3-3.6 0.6 0.2-1.9 
Alcohol 
(25.6) 
0.9 0.6-1.5 1.0 0.7-1.6 0.9 0.5-1.8 1.1 0.6-1.8 
NSAID-use 
(32.6) 
1.8 0.9-3.2 1.7 0.9-3.1 0.6 0.3-1.6 0.4 0.2-0.8 
H.pylori+ 
(78.1) 
2.4 1.2-4.8 3.5 1.6-7.5 0.6 0.3-1.5 0.2 0.1-0.4 
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Discussion
In this study, H. pylori infection was associated with a sta-
tistically significant increase in prevalence of  duodenal 
and gastric ulceration, table 2 and 5. Early studies noted a 
high incidence of  H. pylori infection in patients with DU8; 
subsequent reviews confirmed that H. pylori is detectable 
in 80 - 95 percent of  these patients9. While the associa-
tion between H. pylori and DU is strong, it is not specific 
as it is also causally linked with GU10.
In this study, majority of  gastric ulcers were distal in loca-
tion. Pre-pyloric and antral gastric ulcers accounted for 
90.8% of  all GUs. Of  note, duodenal ulcers and pre-
pyloric gastric ulcers share similar patterns of  gastric 
inflammation: an initial antral-predominant gastritis pro-
ducing an increased acid response with H. pylori infection; 
deemed a marker for duodenal ulcer diathesis11.
Gastric cancer did not achieve statistical significance with 
H. pylori in this study. However, epidemiological studies 
demonstrate a strong correlation between H. pylori infec-
tion and non-cardia gastric cancer12. Additionally, intes-
tinal-type gastric cancer, the dominant gastric adenocar-
cinoma sampled, has been shown to be more strongly 
associated with H. pylori in comparison with diffuse-type 
GCA13,14. On the contrary, a previous study in Accra, did 
not find an association between H. pyloriand gastric can-
cer4. However, the number of  GCA cases in our sample 
population and this preceding study were relatively small, 
possibly under-estimating the H. pylori prevalence.
Non-ulcer dyspepsia had a significantly lower prevalence 
of  H. pylori infection (53.1%) when compared with ulcer 
dyspepsia (83-88%). This would be supported by studies 
showing no correlation with infection in such patients 4,15-
17. Eradication of  H. pylori was however associated with 
a small but significant benefit, with treatment of  14 pa-
tients needed to cure one case of  NUD18.   
In Accra, (32.6%) n=79, of  patients sampled at the Ter-
tiary Centre, KBTH had a history of  NSAID-use, mainly 
as an analgesic for musculoskeletal pain. Non-steroidal 
anti-inflammatory drugs are popular because of  their ver-
satility and effectiveness as analgesics, anti-pyretics, and 
as anti-inflammatory agents. In a North-Americanstudy, 
27% of  elderly people were prescribed NSAIDs over a 
six-month period19. The frequency of  its use was report-
edly higher in another study, where 40% of  elderly people 
received at least one NSAID prescription annually19. It 
exerts its ulcerogenic effect primarily as a consequence of  
inhibition of  COX-1 thereby reducing mucosal genera-
tion of  protective prostaglandins such as PGE2,20.
In Ghana, we found an increased prevalence of  peptic 
ulcer disease in patients using prescription or over-the-
counter NSAIDs, table 4.
 
NSAID-induced gastric ulcers typically occur in the 
gastric antrum and pre-pyloric-area and are frequently 
multiple21. A five-year retrospective analysis of  NSAID-
induced peptic ulceration showed a high incidence of  
pre-pyloric ulcers in NSAID-users when compared with 
a control group21. Furthermore, peptic ulcers in two or 
more anatomical sites were more prevalent in the pa-
tients on NSAID-therapy21. The distribution of  DUs and 
pre-pyloric GUs experienced in this study may therefore 
reflect the significant use of  NSAIDs in an H. pylori en-
demic area. 
We also found a statistically significant association be-
tween NSAID-use in Ghana with an increased prevalence 
of  DU in H. pylori-positive patients (p = 0.003). The re-
lationship between NSAID-use, H. pylori and peptic ulcer 
disease is complex:  The role of  H. pylori in NSAID-naïve 
patients seems to be different from those on long-term 
therapy. Patients who had eradication of  H. pylori before 
NSAID treatment have been shown to have a marked 
reduction in short-term ulcer risk22 while H. pylori eradica-
tion in patients already on long-term NSAID treatment 
did not decrease incidence of  peptic ulcer disease or its 
complications23,24. H. pylori therefore exerts a greater in-
fluence on ulcer risk on initiation of  NSAID therapy than 
during long-term use.
The cross-sectional design of  the study meant we were 
unable to assess the temporal relationship between risk 
factors and outcomes.  Additionally, patient selection in 
the main tertiary centre is likely to be associated with 
relatively more severe cases which may not be generaliz-
able to the wider population. The main objective of  the 
study was to investigate the relationship between H. pylori, 
NSAIDs and gastroduodenal disease therefore patients 
with oesophageal disease were excluded. This study could 
not differentiate between duration of  NSAID therapy 
and risk of  gastro-duodenal disease in symptomatic pa-
tients.
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In this study, NSAID gastro-duodenal injury has been 
shown to be common in a H. pylori endemic area, typi-
cally presenting as distal gastric ulcers in symptomatic 
patients.. It also had an additive effect on DU risk in H. 
pylori-positive patients with a higher DU prevalence in 
such patients.It strengthens the need for awareness on 
the adverse GI effects of  NSAIDs in an H. pylori endem-
ic area. Additionally it highlights the need for H. pylori 
eradication to be considered in infected patients who are 
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